Hepatocellular carcinoma in F0 livers: Clinical and prognostic insights

doi:10.4251/wjgo.v18.i4.115576

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 4

This Article

(29)

(23)

(0)

(16)

(567)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Apr 15, 2026; 18(4): 115576
Published online Apr 15, 2026. doi: 10.4251/wjgo.v18.i4.115576

Table 1 Comparison of background characteristics between F0 and F4 hepatocellular carcinoma, mean ± SD

	F0 HCC (n = 42)	F4 HCC (n = 105)	P value
Sex (male/female)	36/6	62/43	0.002
Age (year)	77.9 ± 7.5	70.2 ± 8.1	< 0.001
Body mass index (kg/m²)	23.6 ± 3.2	24.1 ± 3.6	0.481
Platelet count (10⁴/μL)	20.7 ± 5.3	11.9 ± 7.8	< 0.001
Albumin (g/dL)	3.9 ± 0.6	3.8 ± 0.4	0.302
Total bilirubin (g/dL)	0.7 ± 0.3	0.9 ± 0.3	0.011
Aspartate aminotransferase (U/L)	42.3 ± 48.0	42.0 ± 21.6	0.958
Alanine aminotransferase (U/L)	28.1 ± 32.4	34.1 ± 23.2	0.216
Gamma-glutamyl transpeptidase (U/L)	114 ± 171	81.4 ± 82.1	0.249
Prothrombin time (%)	101 ± 17.7	87.7 ± 17.7	< 0.001
Alpha-fetoprotein (ng/mL)	2981 ± 6988	2804 ± 18478	0.956
Des-gamma-carboxy prothrombin (mAU/mL)	34031 ± 138072	4333 ± 28027	0.222
Albumin-bilirubin grade	-2.61 ± 0.46	-2.46 ± 0.39	0.056
Fibrosis-4 index	3.14 ± 2.52	5.47 ± 2.99	< 0.001
Aspartate aminotransferase to platelet ratio index	0.74	1.45	< 0.001
Hypertension (yes/no)	28/14	59/46	0.243
Diabetes mellitus (yes/no)	19/23	35/70	0.176
Cardiovascular disease (yes/no)	10/32	16/89	0.219
Significant alcohol use (yes/no)	16/26	37/68	0.744
Etiology (B/C/negative for both hepatitis B and C)	5/4/33	22/54/30	< 0.001
Tumor number (solitary/multiple)	37/5	79/26	0.371
Largest tumor diameter (mm)	84.7 ± 44.2	57.2 ± 37.6	0.035
Tumor differentiation (well/moderate/poor)	13/26/3	20/65/12	0.337
Vascular invasion (yes/no)	26/16	84/21	0.034

HCC: Hepatocellular carcinoma.

Full Size Table

Citation: Endo M, Honda K, Tokumaru T, Saito T, Uchida T, Iwao M, Arakawa M, Seike M, Kodama M, Masuda T, Endo Y, Inomata M, Murakami K, Mizukami K. Hepatocellular carcinoma in F0 livers: Clinical and prognostic insights. World J Gastrointest Oncol 2026; 18(4): 115576
URL: https://www.wjgnet.com/1948-5204/full/v18/i4/115576.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i4.115576

Endo M, Honda K, Tokumaru T, Saito T, Uchida T, Iwao M, Arakawa M, Seike M, Kodama M, Masuda T, Endo Y, Inomata M, Murakami K, Mizukami K. Hepatocellular carcinoma in F0 livers: Clinical and prognostic insights. World J Gastrointest Oncol 2026; 18(4): 115576 [DOI: 10.4251/wjgo.v18.i4.115576]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.